To include your compound in the COVID-19 Resource Center, submit it here.

FDA issues handful of new PDUFA dates

With the government shutdown resolved, FDA has accepted a handful of applications for review, according to company announcements early this week.

FDA granted Priority Review to two applications from Genentech Inc. for entrectinib and polatuzumab vedotin.

Entrectinib, an inhibitor of ROS1, TrkA, TrkB, TrkC

Read the full 436 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE